Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating a combination of four drugs -- lenalidomide, bortezomib,
dexamethasone and elotuzumab -- as therapy for newly diagnosed multiple myeloma.